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Abstract
It is estimated that about 60–70% of Cystic Fibrosis patients develop Pseudomonas aeruginosa chronic infection,
with progressive loss of lung function, as well as increased antibiotic resistance and mortality.
The current strategy is to maintain lung function by chronic suppressive antipseudomonas antibiotic therapy.
Tobramycin inhalation solution was the first approved aerosolised antibiotic to be used against P. aeruginosa;
inhalatory tobramycin frequency of administration is twice daily and inhalation time is estimated to be 15 to 20 min.
From the pharmacokinetic point of view, aminoglycosides are dose-dependent antibiotics and therefore once-daily
dosing intravenous regimens have shown to be superior to the conventional multiple daily dosing. Therefore, there is
no pharmacological reason to prefer the b.i.d administration as it is usually performed in current clinical practice.
Should this be confirmed also for inhalatory route, the use of once-daily dosed aerosolized tobramycin could be an
important step in making treatment burden easier in CF patients.
The aim of this proof of concept study was to explore the effectiveness of treatment with once daily inhaled
tobramycin in reducing P. aeruginos a density in sputum of chronically infected patients.
Keywords: P. aeruginosa chronic infection, Tobramycin, Aerosolised antibiotic therapy, Cystic fibrosis
It is estimated that during their lifetime about 60–70%
of Cystic Fibrosis patients develop P. aeruginosa chronic
infection, with progressive loss of lung function, as well
as increased morbidity and mortality [1]. In addition, the
massive use of antibiotics during bronchial exacerbations
is associated with the selection of antibiotic resistance [2].
Commonly, a period of intermittent colonization by P.
aeruginosa precedes the establishment of chronic in-
fection and, in this window, efforts are made to ob-
tain bacterial eradication by means of standardized
antibiotic strategies.
Once infection is established, the current strategy is to
maintain lung function by chronic suppressive antipseudo-
monas antibiotic therapy. Alongside the more traditional
routes of administration (oral or IV), aerosol delivery has
become a notable complementary strategy [3, 4].
Tobramycin inhalation solution (TIS) was the first ap-
proved aerosolised antibiotic to be used against P. aeru-
ginosa (FDA, 1998). TIS frequency of administration is
twice daily and inhalation time is estimated to be 15 to
20 min (excluding time for maintenance and disinfection
of the nebulizer). Given the heavy burden of care in CF,
attempts to reduce the time of administration have been
discussed and a great number of studies addressing new
delivery strategies have been reported [5, 6].
From the pharmacokinetic point of view, aminoglyco-
sides are dose-dependent antibiotics and therefore once-
daily dosing regimens have shown to be superior to the
conventional multiple daily dosing [7]. Therefore, there is
no pharmacological reason to prefer the b.i.d administra-
tion as it is usually performed in current clinical practice.
Pharmacokinetic data on sputum concentration of tobra-
mycin following aerosol administration are inconclusive
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[8] and recent data seems to indicate the possible efficacy
of using once daily tobramycin in reducing P. aeruginosa
bacterial load in chronic sinusitis in CF [9]. Should this be
confirmed, the use of once-daily dosed aerosolized tobra-
mycin could be an important step in making treatment
burden easier in CF patients.
The aim of this proof of concept study was to explore
the effectiveness of treatment with once daily inhaled
tobramycin in reducing P. aeruginosa density in sputum
of chronically infected patients.
A once daily dose regimen of 300 mg aerosolised
tobramycin [Bramitob ®, Chiesi Farmaceutici] was ad-
ministered for one month in adult CF patients with
chronic P. aeruginosa infection, after a 4-week wash-out
period of antispeudomonal therapy.
Patients were evaluated at T1, at the end of wash-out
period, at T2, after 7 days of treatment, at T3, after
21 days of treatment and at T4, at the end of the 28-day
treatment period.
The following parameters were analysed:
– Maximum bacterial load in sputum. (Max load)
– Mean bacterial load in sputum. (Mean load).
– Tobramycin-resistant P. aeruginosa strains (n°).
– Tobramycin-resistant P. aeruginosa strains (%).
– change in daily sputum amount.
– change in Forced Expiratory Volume in the first
second (FEV1).
– change of systemic inflammatory markers, C-
Reactive Proteine (CRP) and Procalcitonin (PCT).
– change in serum cytokines profile; Interleukin 2;
(IL2), Interleukin 4 (IL4); Interleukin 6 (IL6);
Interleukin 8 (IL8); Interleukin 10 (IL10); Vascular
Endothelial Growth Factor (VEGF); Interferon
Gamma (INFγ); Tumor Necrosis Factor Alfa
(TNFα); Interleukin 1a (IL1a); Interleukin 1b (IL1b);
Monocyte Chemoattractant Protein 1 (MCP1);
Epidermal growth factor (EGF).
A comparison between data obtained at basal time
(T1) and at T2, T3 and T4 was performed.
A total of 12 patients [7 males/2 females, mean age
(SD) 35.1 (8.1) years] with chronic P. aeruginosa infec-
tion were enrolled. Nine patients completed the study, 2
were excluded from the study because sputum culture
tests resulted negative for P aeruginosa before the first
dose of tobramycin, and 1 patient withdrew consent.
No statistically significant differences in the Max and
Mean bacterial load expressed as median and inter quar-
tile range (IQR) at the different time points, were found;
Fig. 1 Mean bacterial load trend for each patient. T1: end of wash-out period; T2: 7 days after the beginning of treatment; T3: 21 days after the
beginning of treatment; T4: end of the 28-day treatment
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respectively 5.0 (4.5–5.5) log 10 CFU at T1, 5.0 (4.5–5–5)
log 10 CFU at T2, 5.0 (5.0–6.0) log 10 CFU at T3 and 6.0
(5.0–6.0) log 10 CFU at T4; p (ANOVA) = 0,27 and 4.7
(3.9–4.9) log 10 CFU at T1, 4.7 (4.0–5.0) log 10 CFU at
T2, 4.3 (4.3–5.3) log 10 CFU at T3 and 5.7 (3.7–6.0) log
10 CFU at T4 p (ANOVA) = 0.50. No difference in the
mean (IQR) percent of predicted FEV1 at the different
time points was found, 64 (60.50–80.00)% at T1 68.00
(59.00–79.50)% at T2, 69.00 (58.50–83.50)% at T3 and 67
(57.00–77.50)% at T4 p ANOVA= 0.97. Despite this, no
increase in the number of resistant bacterial strains was
registered and no difference in the mean (IQR) sputum
24-h production at the different time points were found,
25 (11.25–27.00) ml/day at T1, 20.00 (8.70–27.50) ml/day
at T2, 15.00 (11.25–25.00) ml/day at T3 and 25.00
(11.25–30.00) ml/day at T4 p ANOVA = 0.93.
No difference in inflammatory markers was found,
CRP expressed as median and IQR, at the different time
points were 0.29 (0.21–0.44) mg/dl at T1, 0.39 (0.25–
0.83) mg/dl at T2, 0.31 (0.25–0.56) mg/dl at T3 and 0.32
(0.20–1.36) mg/dl at T4 p ANOVA 0.86; PCT expressed
as median and IQR was 0.05 (0.03–0.06) μg/ml at T1,
0.05 (0.04–0.06) μg/ml at T2, 0.31 (0.25–0.56) μg/ml at
T3 and 0.32 (0.20–1.36) μg/ml at T4 p ANOVA = 0.86.
No difference in the cytokine profile was found at the
different time points.
The analysis of the mean bacterial load showed reduc-
tions in some patients, but not in others, see Fig. 1.
The main finding is that none of the selected out-
comes (lung function, bacterial load, inflammation and
cytokine profile) significantly changed during and at the
end of the study, but some response may be observed in
selected patients.
Conclusion
These results may be related to the small sample size,
but the lack of any positive trend suggests that the use
of 300 mg of once daily areosolised tobramycin is insuffi-
cient in treating the majority of CF patients with chronic
P aeruginosa infection. However, individual patients did
benefit from once daily aerosolized tobramycin. Moreover,
no increase in inflammatory and cytokine profile was
found and no evidence of resistant strain selection
emerged showing that in all patients some form of control
of infection and inflammation was attained.
This leads us to conclude that it would be interesting
to further explore the use of tobramycin with a phase II
study with a dose-finding design and to confirm the ex-
istence of patients who are responders to once daily
aerosolised tobramycin.
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